ReviewEClinicalMedicine2024
Outcomes that matter to patients with cancer: living longer and living better.
Review in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020-2024).Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026Pooled it
- Scoping Review of Patient-Centered Outcomes in Gastrointestinal Cancer Care.Psycho-oncology · 2026Article
- Association of metabolic markers, inflammatory biomarkers, and sedentary time with comorbidities among cancer patients: Results from NHANES 2021-2023.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Accelerated radiotherapy pathways: a systematic review on same-day planning and treatment in radiation oncology.Clinical and translational radiation oncology · 2026Review
- A Delphi Study to Identify Priority Indicators for Formulary Selection of Innovative Anticancer Drugs in China.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Review
- The Mediating Roles of Self-Efficacy, Resilience, and Social Support in the Relationship Between Clinical Factors and Adaptation to Chronic Disease.Journal of multidisciplinary healthcare · 2026Article
- Mendelian randomization analysis reveals protective effects of LIFR and CXCL5 against breast cancer risk.Discover oncology · 2025Article
- What is the role of common sense oncology in the Western Pacific?The Lancet regional health. Western Pacific · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncologists and cancer patients generally agree that the primary goals of advanced cancer treatment are to lengthen and/or improve patient survival. Yet over the last two decades, clinical trials of new cancer treatments have moved away from measuring outcomes that matter to patients. Increasingly, new drugs for advanced cancer treatment reach the market by demonstrating improvements in surrogate endpoints such as progression-free survival (PFS), which is not a measure of how a patient feels, functions, or survives. Research has shown that when patients are fully informed about the meaning of PFS, about half would not choose additional treatment for any magnitude of gain in PFS in the absence of an overall survival improvement. It's time to get back to designing trials that answer clinically meaningful questions and measure the outcomes that truly matter to patients. Engaging educated patient advocates in meaningful ways in clinical trial design and reporting would be a step in this direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.